BioPharma Resources

Investigational drug · Phase 2

FB825

Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Allergic Asthma, Atopic Dermatitis.

Phase 2

Last checked: Nov 19, 2026Latest source record: Jun 15, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

2

2 still active

All registered trials

7

Any phase or sponsor naming "FB825"

First trial start

2021

Jul 27, 2021

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "FB825", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Allergic Asthma
  • Atopic Dermatitis

Approved drugs for the same conditions: Atopic dermatitis (eczema) · Asthma · Immunology and inflammation · Respiratory · Dermatology

Largest trials

Live from ClinicalTrials.gov: studies naming "FB825" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 0 on PubMed

No PubMed records name it yet, which is common for early code-named drugs.

Also in development for Allergic Asthma

  • LP-003SinglePhase 39 trials

    Longbio Pharma · Allergic Asthma, Chronic Spontaneous Urticaria (CSU), Peanut Allergies

  • JYB1904RPT904, ozureprubartPhase 35 trials

    Jemincare · Chronic Spontaneous Urticaria, Perennial Allergic Rhinitis, Immune System Diseases

  • 000 MM09Phase 32 trials

    Inmunotek S.L. · Rhinitis, Allergic, Rhinoconjunctivitis, Asthma, Allergic

  • EP-088_MM09Phase 32 trials

    Inmunotek S.L. · Allergic Rhinitis, Allergic Rhinoconjunctivitis, Allergic Asthma

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.